JP2021501198A - フルオレンの誘導体を用いて造血幹細胞を増殖する組成物および方法 - Google Patents

フルオレンの誘導体を用いて造血幹細胞を増殖する組成物および方法 Download PDF

Info

Publication number
JP2021501198A
JP2021501198A JP2020543247A JP2020543247A JP2021501198A JP 2021501198 A JP2021501198 A JP 2021501198A JP 2020543247 A JP2020543247 A JP 2020543247A JP 2020543247 A JP2020543247 A JP 2020543247A JP 2021501198 A JP2021501198 A JP 2021501198A
Authority
JP
Japan
Prior art keywords
cells
compound
group
formula
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020543247A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021501198A5 (https=
Inventor
コターリ ジェシー
コターリ ジェシー
ウェブ ティモシー
ウェブ ティモシー
ワン チャン
ワン チャン
Original Assignee
トランスフュージョン ヘルス，リミティド ライアビリティ カンパニー
トランスフュージョン ヘルス，リミティド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トランスフュージョン ヘルス，リミティド ライアビリティ カンパニー, トランスフュージョン ヘルス，リミティド ライアビリティ カンパニー filed Critical トランスフュージョン ヘルス，リミティド ライアビリティ カンパニー
Publication of JP2021501198A publication Critical patent/JP2021501198A/ja
Publication of JP2021501198A5 publication Critical patent/JP2021501198A5/ja
Priority to JP2023198957A priority Critical patent/JP2024015035A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/68—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings and hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/70—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings and hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/22—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/30—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
    • C07C233/33—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/56—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having carbon atoms of carboxamide groups bound to carbon atoms of carboxyl groups, e.g. oxamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/44—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups being part of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/47—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/30—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a six-membered aromatic ring being part of a condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C35/48—Halogenated derivatives
    • C07C35/52—Alcohols with a condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/657—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings
    • C07C49/665—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings a keto group being part of a condensed ring system
    • C07C49/675—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings a keto group being part of a condensed ring system having three rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/687—Unsaturated compounds containing a keto groups being part of a ring containing halogen
    • C07C49/697—Unsaturated compounds containing a keto groups being part of a ring containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/12—Acetic acid esters
    • C07C69/16—Acetic acid esters of dihydroxylic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/28—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with dihydroxylic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/46—Amines, e.g. putrescine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020543247A 2017-10-27 2018-10-26 フルオレンの誘導体を用いて造血幹細胞を増殖する組成物および方法 Pending JP2021501198A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023198957A JP2024015035A (ja) 2017-10-27 2023-11-24 フルオレンの誘導体を用いて造血幹細胞を増殖する組成物および方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762578297P 2017-10-27 2017-10-27
US62/578,297 2017-10-27
US201762583328P 2017-11-08 2017-11-08
US62/583,328 2017-11-08
PCT/US2018/057783 WO2019084452A1 (en) 2017-10-27 2018-10-26 COMPOSITIONS AND METHODS FOR PRODUCING EXPANDED HEMATOPOIETIC STEM CELLS USING FLUORENE DERIVATIVES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023198957A Division JP2024015035A (ja) 2017-10-27 2023-11-24 フルオレンの誘導体を用いて造血幹細胞を増殖する組成物および方法

Publications (2)

Publication Number Publication Date
JP2021501198A true JP2021501198A (ja) 2021-01-14
JP2021501198A5 JP2021501198A5 (https=) 2021-12-02

Family

ID=66247033

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020543247A Pending JP2021501198A (ja) 2017-10-27 2018-10-26 フルオレンの誘導体を用いて造血幹細胞を増殖する組成物および方法
JP2023198957A Pending JP2024015035A (ja) 2017-10-27 2023-11-24 フルオレンの誘導体を用いて造血幹細胞を増殖する組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023198957A Pending JP2024015035A (ja) 2017-10-27 2023-11-24 フルオレンの誘導体を用いて造血幹細胞を増殖する組成物および方法

Country Status (9)

Country Link
US (2) US11459293B2 (https=)
EP (1) EP3700334B1 (https=)
JP (2) JP2021501198A (https=)
KR (1) KR102770289B1 (https=)
CN (1) CN111885914B (https=)
AU (1) AU2018354418B2 (https=)
CA (1) CA3079959A1 (https=)
IL (1) IL273978B2 (https=)
WO (1) WO2019084452A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102488238B1 (ko) * 2018-12-13 2023-01-13 동우 화인켐 주식회사 양자점, 이를 포함하는 양자점 발광다이오드, 양자점 필름, 광 변환 수지 조성물, 상기 광 변환 수지 조성물을 이용하여 형성되는 컬러필터, 광 변환 적층기재 및 상기 컬러필터 또는 상기 광 변환 적층기재를 포함하는 화상표시장치
AU2020265737A1 (en) * 2019-05-01 2021-12-02 Immunebridge Inc. Methods of making oligopotent and unipotent precursors
CA3138280A1 (en) * 2019-05-01 2020-11-05 Transfusion Health, Llc Compositions and methods of making expanded hematopoietic stem cells using derivatives of carbazole
CN114787342A (zh) * 2019-12-16 2022-07-22 广州辑因医疗科技有限公司 扩增造血干细胞的小分子化合物及其组合
CN111019886B (zh) * 2019-12-18 2023-02-03 卓越细胞工程(香港)有限公司 新的干性因子和其用于培养胚胎干细胞的方法或培养体系

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3466274A (en) * 1964-07-06 1969-09-09 Manuf Prod Pharma Fluoreno-(1,9-ef)-1,4-diazepine-1-oxides and 1,3-diazafluoranthene-1-oxides
GB1314899A (en) * 1970-07-28 1973-04-26 Sterling Winthrop Group Ltd Thiosemicarbazones processes for their preparations and compositions incorporating them
US3947593A (en) * 1973-06-15 1976-03-30 Richardson-Merrell Inc. Pharmaceutically useful bis-amine derivatives
EP0005288A1 (en) * 1978-04-21 1979-11-14 Chimac Societe Anonyme Derivatives of 1-amino-fluoren-9-one and their use as herbicides
WO1994005276A1 (en) * 1992-09-08 1994-03-17 Morgan Lee R Cytotoxic compounds
JPH0761949A (ja) * 1993-06-18 1995-03-07 Otsuka Pharmaceut Co Ltd 中枢及び末梢神経変性修復又は保護剤
WO2004032975A2 (en) * 2002-10-04 2004-04-22 The Trustees Of The University Of Pennsylvania Biphenyls and fluorenes as imaging agents in alzheimer's disease
WO2005079845A1 (ja) * 2004-02-20 2005-09-01 Astellas Pharma Inc. 片頭痛予防薬
JP2008511156A (ja) * 2004-09-24 2008-04-10 エルジー・ケム・リミテッド 新しい有機発光素子材料およびこれを用いた有機発光素子（７）
CN101418269A (zh) * 2008-09-27 2009-04-29 大连理工大学 一种链霉菌及其在还原芳香酮中的应用
JP2010538968A (ja) * 2007-06-01 2010-12-16 ザ トラスティーズ オブ プリンストン ユニバーシティ 宿主細胞代謝経路の調節によるウイルス感染治療
CN102174320A (zh) * 2011-03-17 2011-09-07 上海大学 具有扭曲结构的蓝色电致发光材料及其制备方法
CN103086859A (zh) * 2011-11-08 2013-05-08 清华大学 2,4-二羟基-5,6-取代-1-卤代苯衍生物、其合成方法及其应用
US20140135359A1 (en) * 2012-11-12 2014-05-15 Louis C. Martineau Methods of designing, preparing, and using novel protonophores
CN104557862A (zh) * 2014-12-15 2015-04-29 苏州云轩医药科技有限公司 具有Wnt信号通路抑制活性的杂环化合物
JP2015515448A (ja) * 2012-02-27 2015-05-28 ブリティッシュ コロンビア キャンサー エイジェンシー ブランチＢｒｉｔｉｓｈ Ｃｏｌｕｍｂｉａ Ｃａｎｃｅｒ Ａｇｅｎｃｙ Ｂｒａｎｃｈ 癌におけるエピジェネティックな欠陥を修復するためのエフェクタータンパク質相互作用のリプログラミング
JP2016538306A (ja) * 2013-11-27 2016-12-08 アメリカ合衆国 複素環化合物及びその使用方法
JP2017513897A (ja) * 2014-04-22 2017-06-01 ウニヴェルシテ ド モントリオールＵｎｉｖｅｒｓｉｔｅ Ｄｅ Ｍｏｎｔｒｅａｌ 化合物および造血幹細胞および／または造血前駆細胞の増大におけるその使用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK575387A (da) * 1986-11-04 1988-05-05 Otsuka Pharma Co Ltd Hydrofluorenderivater, fremgangsmaade til fremstilling deraf og praeparater indeholdende saadanne forbindelser
JP2622197B2 (ja) * 1990-03-01 1997-06-18 三共株式会社 １３−エーテル置換ミルベマイシン誘導体
AU700386B2 (en) * 1995-10-16 1999-01-07 Kyowa Hakko Kogyo Co. Ltd. Triciclic compounds
CO5170528A1 (es) * 1999-05-28 2002-06-27 Smithkline Beecham Corp Antagonistas de los receptores de la il-8 nistas del recpetor de la il-8
US20020035104A1 (en) * 2000-08-18 2002-03-21 Genentech, Inc. Integrin receptor inhibitors
BRPI0116728B1 (pt) * 2001-01-05 2018-10-30 Pfizer Inc. anticorpos para receptor de fator de crescimento i semelhante à insulina
BRPI0410439A (pt) * 2003-05-19 2006-06-06 Irm Llc compostos e composições imunossupressoras
WO2005032598A1 (en) * 2003-10-02 2005-04-14 The General Hospital Corporation Polybiotin compounds for magnetic resonance imagining and drug delivery
EP1755574A4 (en) 2004-04-06 2009-05-13 Semafore Pharmaceuticals Inc PTEN INHIBITORS
WO2007016762A1 (en) * 2005-08-10 2007-02-15 Quest Pharmatech Inc. Perylenequinone derivatives and uses thereof
SI2032606T1 (sl) * 2006-05-30 2014-02-28 Genentech, Inc. Protitelesa in imunokonjugati in njihove uporabe
CN101506154B (zh) * 2006-08-21 2015-06-17 辛塔制药公司 用于治疗增生性疾病的化合物
EP2148569B1 (en) * 2007-04-23 2014-07-16 Stowers Institute for Medical Research Methods and compositions for hematopoeitic stem cell self-renewal
TW200916472A (en) * 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
JP5645658B2 (ja) * 2007-07-10 2014-12-24 カーネギー メロン ユニバーシティー 核磁気共鳴技術のための細胞標識を製造するための組成物及び方法
AU2008305581C1 (en) * 2007-09-26 2014-12-11 Celgene Corporation 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
FR2929276B1 (fr) * 2008-04-01 2010-04-23 Servier Lab Nouveaux derives de diosmetine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20100310456A1 (en) * 2009-06-04 2010-12-09 General Electric Company Imaging of myelin basic protein
JP5761718B2 (ja) * 2009-08-07 2015-08-12 国立大学法人東京農工大学 新規糖転移酵素、新規糖転移酵素遺伝子および新規糖供与体化合物
JP5984217B2 (ja) 2010-06-15 2016-09-06 セルラー ダイナミクス インターナショナル， インコーポレイテッド 少量の末梢血からの人工多能性幹細胞の作製
MX344772B (es) * 2011-01-28 2017-01-06 Univ Kentucky Res Found Analogos de estilbeno y metodos para tratar cancer.
WO2013033206A2 (en) * 2011-08-29 2013-03-07 University Of Rochester Compositions and methods for inhibiting ccl3
US20200155609A1 (en) 2017-05-22 2020-05-21 Transfusion Health Llc Compositions and methods of making expanded hematopoietic stem cells using pten inhibitors

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3466274A (en) * 1964-07-06 1969-09-09 Manuf Prod Pharma Fluoreno-(1,9-ef)-1,4-diazepine-1-oxides and 1,3-diazafluoranthene-1-oxides
GB1314899A (en) * 1970-07-28 1973-04-26 Sterling Winthrop Group Ltd Thiosemicarbazones processes for their preparations and compositions incorporating them
US3947593A (en) * 1973-06-15 1976-03-30 Richardson-Merrell Inc. Pharmaceutically useful bis-amine derivatives
EP0005288A1 (en) * 1978-04-21 1979-11-14 Chimac Societe Anonyme Derivatives of 1-amino-fluoren-9-one and their use as herbicides
WO1994005276A1 (en) * 1992-09-08 1994-03-17 Morgan Lee R Cytotoxic compounds
JPH0761949A (ja) * 1993-06-18 1995-03-07 Otsuka Pharmaceut Co Ltd 中枢及び末梢神経変性修復又は保護剤
WO2004032975A2 (en) * 2002-10-04 2004-04-22 The Trustees Of The University Of Pennsylvania Biphenyls and fluorenes as imaging agents in alzheimer's disease
WO2005079845A1 (ja) * 2004-02-20 2005-09-01 Astellas Pharma Inc. 片頭痛予防薬
JP2008511156A (ja) * 2004-09-24 2008-04-10 エルジー・ケム・リミテッド 新しい有機発光素子材料およびこれを用いた有機発光素子（７）
JP2010538968A (ja) * 2007-06-01 2010-12-16 ザ トラスティーズ オブ プリンストン ユニバーシティ 宿主細胞代謝経路の調節によるウイルス感染治療
CN101418269A (zh) * 2008-09-27 2009-04-29 大连理工大学 一种链霉菌及其在还原芳香酮中的应用
CN102174320A (zh) * 2011-03-17 2011-09-07 上海大学 具有扭曲结构的蓝色电致发光材料及其制备方法
CN103086859A (zh) * 2011-11-08 2013-05-08 清华大学 2,4-二羟基-5,6-取代-1-卤代苯衍生物、其合成方法及其应用
JP2015515448A (ja) * 2012-02-27 2015-05-28 ブリティッシュ コロンビア キャンサー エイジェンシー ブランチＢｒｉｔｉｓｈ Ｃｏｌｕｍｂｉａ Ｃａｎｃｅｒ Ａｇｅｎｃｙ Ｂｒａｎｃｈ 癌におけるエピジェネティックな欠陥を修復するためのエフェクタータンパク質相互作用のリプログラミング
US20140135359A1 (en) * 2012-11-12 2014-05-15 Louis C. Martineau Methods of designing, preparing, and using novel protonophores
JP2016538306A (ja) * 2013-11-27 2016-12-08 アメリカ合衆国 複素環化合物及びその使用方法
JP2017513897A (ja) * 2014-04-22 2017-06-01 ウニヴェルシテ ド モントリオールＵｎｉｖｅｒｓｉｔｅ Ｄｅ Ｍｏｎｔｒｅａｌ 化合物および造血幹細胞および／または造血前駆細胞の増大におけるその使用
CN104557862A (zh) * 2014-12-15 2015-04-29 苏州云轩医药科技有限公司 具有Wnt信号通路抑制活性的杂环化合物

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"RN 500538-48-7 REGISTRY", DATABASE REGISTRY [ONLINE] RETRIEVED FROM STN, JPN7022004895, 25 March 2003 (2003-03-25), pages 17 - 2022, ISSN: 0005264461 *
"RN 908823-02-9 REGISTRY", DATABASE REGISTRY [ONLINE] RETRIEVED FROM STN, JPN7022004896, 27 September 2006 (2006-09-27), pages 11 - 2022, ISSN: 0005264462 *
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 19, no. 11, JPN6022043859, 2009, pages 3045 - 3049, ISSN: 0005264460 *
BIOORGANIC & MEDICINAL CHEMISTRY, vol. 9, no. 10, JPN6022043852, 2001, pages 2673 - 2682, ISSN: 0005264455 *
CHEMICAL BIOLOGY & DRUG DESIGN, vol. 88, no. 5, JPN6022043858, 2016, pages 730 - 739, ISSN: 0005264459 *
CHEMICAL COMMUNICATIONS, vol. 8, JPN6022043856, 2006, pages 865 - 867, ISSN: 0005264457 *
JOURNAL OF ORGANIC CHEMISTRY, vol. 23, JPN6022043853, 1958, pages 799 - 803, ISSN: 0005264456 *
JOURNAL OF PHYSICAL CHEMISTRY A, vol. Vol.103, No.20), JPN6022043855, 1999, pages 3837 - 3842, ISSN: 0005264454 *
MEDCHEMCOMM, vol. 6, no. 7, JPN6022043857, 2015, pages 1278 - 1284, ISSN: 0005264458 *

Also Published As

Publication number Publication date
AU2018354418B2 (en) 2025-09-11
IL273978B1 (en) 2024-05-01
CN111885914B (zh) 2022-05-13
IL273978B2 (en) 2024-09-01
KR20200094141A (ko) 2020-08-06
AU2018354418A1 (en) 2020-05-14
KR102770289B1 (ko) 2025-02-19
EP3700334A4 (en) 2021-07-21
US20200255371A1 (en) 2020-08-13
US20230112489A1 (en) 2023-04-13
EP3700334A1 (en) 2020-09-02
CN111885914A (zh) 2020-11-03
WO2019084452A1 (en) 2019-05-02
US11459293B2 (en) 2022-10-04
EP3700334B1 (en) 2026-04-08
CA3079959A1 (en) 2018-10-26
IL273978A (en) 2020-05-31
JP2024015035A (ja) 2024-02-01

Similar Documents

Publication Publication Date Title
JP2021501198A (ja) フルオレンの誘導体を用いて造血幹細胞を増殖する組成物および方法
JP7352807B2 (ja) アリール炭化水素受容体アンタゴニスト及びその使用
JP7499698B2 (ja) 化合物及び幹細胞及び／又は前駆細胞の増殖におけるその使用
AU2013212457A1 (en) Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells
KR20190039988A (ko) 조혈 줄기 및 전구 세포의 생성, 증식 및 분화를 위한 치환된 아졸 유도체
US20200155609A1 (en) Compositions and methods of making expanded hematopoietic stem cells using pten inhibitors
US20220378740A1 (en) Compositions and methods of making expanded hematopoietic stem cells using derivatives of carbazole
US20220315895A1 (en) Methods of making oligopotent and unipotent precursors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211025

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221018

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230417

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231128

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231214

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260129